Click on the “Search Now” button to search for research studies enrolling people like you. Need help getting started? Click on “Tips for Searching Studies” to find resources and assistance to help you find studies.

Search Results: Prevention, Detection & Risk + Screening & Early Detection (12 results)

1 through 12 of 12
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

People at high risk for prostate cancer due to an inherited mutation

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

More info
Men at High Genetic Risk for Prostate Cancer


Men at High Genetic Risk for Prostate Cancer

The National Cancer Institute has opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, NBN, TP53, CHEK2, PALB2, RAD51C RAD51D, BRIP1, FANCA or ATM mutation. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.

More info
Blood Markers of Early Pancreas Cancer


Blood Markers of Early Pancreas Cancer

The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

More info
Developing a Test for the Detection of Ovarian Cancer


Developing a Test for the Detection of Ovarian Cancer

The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.

More info
Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation


Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

More info
Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations


Research Study to Help Improve Family Communication About Inherited Mutations

The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone.  Participants will be asked to complete a total of 3 surveys.  Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable.  Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials). 

You can get more information or ask to participate in the study by sending an email to:

More info
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families


Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. 

More info
Pancreatic Cancer Screening Study for High Risk People


A Pancreatic Cancer Screening Study for High Risk Individuals

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

More info
Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)


RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.

More info
Study for People with Unexpected Genetic Results


Genomic Services Research Program Study for People with Unexpected Genetic Results

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.

More info
Pancreatic Cancer Early Detection


Pancreatic Cancer Early Detection Program

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

More info


The WISDOM Study: Women Informed to Screen Depending on Measures of risk

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website

More info
Additional Results on Prevention, Detection & Risk + Screening & Early Detection
80 results
Clinical Trial Official Title
NCT04473833 Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
NCT04848051 Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations
NCT04336397 Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
NCT04427527 Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
NCT04940442 Outreach and Choice in Colorectal Cancer Screening
NCT05064410 Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative
NCT05376241 Promoting Informed Choice for Breast Cancer Screening
NCT04464668 Colorectal Cancer Awareness, Research and Education and Screening - Rural Expansion, Access and Capacity for Health
NCT05384535 Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT04450264 Increasing African Immigrant Women's Participation in Breast Cancer Screening
NCT03250078 A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT05004376 Text-based Colorectal Cancer Prevention Pilot
NCT04877912 Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening
NCT05036096 Cone Beam Breast CT for Breast Cancer Screening
NCT02478892 Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT03699995 MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT03937453 A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus
NCT05298605 Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT04890054 Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT05129605 Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT03407417 A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT03474913 Upright MRI for Prostate Cancer Screening
NCT04980157 CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
NCT05055843 Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
NCT04030507 Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT04313114 The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT04683744 Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
NCT03729115 A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT03640208 Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT04683731 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
NCT05051631 BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT04764292 Screening Contrast-Enhanced Mammography as an Alternative to MRI
NCT04671498 Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study
NCT04348123 Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
NCT04904757 Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT04854304 Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
NCT04192071 Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
NCT04582500 Virtual Colonoscopy Using Omnipaque as a Contrast Agent
NCT04414306 Screen to Save 2: Rural Cancer Screening Educational Intervention
NCT04662879 Early Detection Initiative for Pancreatic Cancer
NCT05257057 Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome
NCT04085510 Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
NCT05551052 CRC Detection Reliable Assessment With Blood
NCT02470273 Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)
NCT04763824 KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice
NCT03623945 Autoantibodies in Breast Cancer Detection
NCT04705363 A Sociolinguistic-enabled Web Application to Develop Precision Health Intervention for African Americans
NCT04086771 Southeast Asian Women's Health Project
NCT05127096 Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
NCT05246839 Informed Choice - Compass
NCT01035112 Magnetic Resonance Imaging of Breast Cancer
NCT03568630 Blood Markers of Early Pancreas Cancer
NCT04259762 Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
NCT05076266 COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
NCT04341129 Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
NCT03984695 Sexual Health Empowerment for Women's Health
NCT03715959 Nipple Aspirate Fluid in Detecting Breast Cancer
NCT05056818 Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT03218423 Longitudinal Performance of Epi proColon
NCT04369053 Prevention of Colorectal Cancer Through Multiomics Blood Testing
NCT03558048 The Effect of IBD Flares on Serum PSA
NCT04331535 The Genomic Medicine at VA Study
NCT02206360 Pancreatic Cancer Early Detection Program
NCT04124900 Telomere Associated Variables (TAVs) in Prostate Cancer
NCT04825834 DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT05445570 Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages
NCT03147430 Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT04583072 Stockholm3 Validation Study in a Multi-Ethnic Cohort
NCT00539162 Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00579514 Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
NCT00579488 Clinical Significance of Germline BRCA Mutations
NCT00843375 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT04967352 Predicting Chronic Pain Following Breast Surgery
NCT04792684 Collection of Samples USOPTIVAL Study
NCT04705168 Study of the Nevisense Device to Assess Atypical Skin Lesions
NCT04570722 Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)
NCT04973007 Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
NCT03789162 Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT04843566 Evaluation of Transperineal Biopsy Under Local Anesthesia
NCT04815876 Transperineal vs. Transrectal MRI-targeted Prostate Biopsy

Research Search Tool Sponsored By:

Merck & Co., Inc.

This resource was made possible through an independent grant from Merck & Co., Inc.